Uncategorized
Data from BioTime’s OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have been accepted and will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii. "BioTime is looking forward to presenting at ARVO, the largest and most respected e